Biolexis Therapeutics leverages its FIELDS™ technology, which involves screening fragments against a protein target library, to generate real/empirical data points and scaffold-like compounds. This data is used to design new drug candidates and accelerate the discovery of novel pre-clinical to clinical stage agents. The company's approach combines modern chemical biology, advanced machine learning, and AI-backed platforms to create active, safe, and efficacious novel chemical entities. By using FIELDS™, Biolexis Therapeutics aims to accelerate drug discovery and development, shorten the path to clinical trials, expedite First-In-Human (FIH) trials, and facilitate the delivery of medicines to patients worldwide. The company focuses on developing small molecule therapeutics for diseases in immunology, oncology, and metabolism, where effective therapies are currently lacking. Founded in 2021 and headquartered in Sandy, Utah, Biolexis Therapeutics was established by Dr. Hari Vankayalapati and Dr. David J. Bearss.